Compare Abbott Laboratories (ABT) vs Huntington Bancshares Incorporated (HBAN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Huntington Bancshares Incorporated — how do they compare? Abbott Laboratories trades at $95.33 (market cap $166.94B), while Huntington Bancshares Incorporated trades at $17.44 (market cap $36.50B). The key difference: Abbott Laboratories is far larger — about 4.6× Huntington Bancshares Incorporated's market cap, and Huntington Bancshares Incorporated pays the higher dividend (3.44%). Which is the better fit depends on your goals.
| ABT | HBAN | |
|---|---|---|
Market Cap | $166.94B | $36.50B |
Sector | Health | Financials |
52-Week High | $136.62 | $19.27 |
52-Week Low | $82.57 | $15.02 |
Enterprise Value | $193.69B | — |
Dividend Yield | 2.63% | 3.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Huntington Bancshares (HBAN) trades at $18.01, up 0.84% with bullish technical indicators and strong analyst support. The stock shows solid fundamentals with Q1 2026 EPS beating expectations at $0.26 vs. $0.23, revenue growth to $8.13B in 2025, and a reasonable P/E of 13.77. Recent news highlights successful Texas expansion and banking tech awards, while cash flow trends show consistent operational strength.
HBAN presents a compelling buy case with 51% analyst buy ratings and a $19.90 price target offering 10% upside. Key opportunities include M&A synergies and digital banking growth, though risks remain from integration challenges and competitive pressures in regional banking markets. The stock's current valuation and growth trajectory support a positive outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Huntington Bancshares Incorporated
Huntington Bancshares is a regional bank holding company headquartered in Columbus, Ohio. The bank has a network of branches and ATMs across eight Midwestern states. Founded in 1866, Huntington National Bank and its affiliates provide consumer, small-business, commercial, treasury management, wealth management, brokerage, trust, and insurance services. Huntington also provides auto dealer, equipment finance, national settlement, and capital market services that extend beyond its core states.
Read more on HBAN →
